Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 5891
License Grant
The Licensee entered into a License Agreement with the Licensor, a private Canadian federal corporation, for a term of 50 years, pursuant to which we acquired an exclusive worldwide License to manufacture, market, and distribute a medical pessary device for the treatment of female urinary incontinence called the Gynecone.
License Property
A pessary is a medical device inserted into the vagina, either to provide structural support, or as a method of delivering medication.
Field of Use
The rights granted apply to the healthcare industry relating to female humans.
IPSCIO Record ID: 26559
License Grant
Licensor hereby appoints and grants to Licensee, and Licensee hereby accepts from Licensor, the exclusive right and license to use, manufacture, market, sell and distribute the Products during the term of this Agreement, upon the terms and conditions contained herein.
License Property
Licensor is a medical device company that develops products for patients in the urogynecology and gynecology markets and has developed, and continues to develop, neurostimulation devices currently being, or proposed to be, marketed under the brand names and trademarks (collectively, the Trademarks) Urgent®, Urgent-PC™ and Urgent-SQ™ (collectively as now existing or hereafter improved, modified or enhanced, the Products).
The Urgent PC Neuromodulation System uses percutaneous tibial nerve stimulation (PTNS) to treat overactive bladder and associated symptoms of urinary urgency, urinary frequency and urge incontinence.
The Urgent PC neuromodulation system is a minimally invasive device designed for office-based treatment of overactive bladder symptoms of urge incontinence, urinary urgency and urinary frequency. This product uses percutaneous tibial nerve stimulation to deliver an electrical pulse that travels to the sacral nerve plexus, a control center for bladder function.
Field of Use
The rights granted apply to the healthcare industry.
IPSCIO Record ID: 1704
License Grant
The Licensee entered into an agreement as licensee to obtain exclusive patent rights covering certain injection-related instrumentation. The Licensor is undisclosed.
Field of Use
The Licensee's business is the manufacture, distribution and sale of an injectable medical device implant used to treat certain forms of urinary incontinence.
IPSCIO Record ID: 27711
License Grant
Under the terms of an agreement with several undisclosed related Licensors the Licensee pays royalties on sales of certain Macroplastique products.
License Property
Macroplastique® Implants is an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence that is primarily due to intrinsic sphincter deficiency. Macroplastique is a soft-textured, permanent implant injected, under endoscopic visualization, around the urethra distal to the bladder neck. It is a proprietary composition of heat vulcanized, solid, soft, irregularly shaped polydimethylsiloxane (solid silicone elastomer) implants suspended in a biocompatible excretable carrier gel.
Field of Use
The Licensee is a global medical device company.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
